DB06363InvestigationalVaccines
tgAAC09 is an investigational vaccine that utilizes an AAV vector to deliver genes that encode HIV proteins. It was under investigation in clinical trials NCT00482027 and NCT00888446 for the treatment...
- Mechanism
- Curator reviewed
tgAAC09 is a vaccine candidate that utilizes an AAV vector to deliver genes that encode HIV proteins. The vaccine is designed to stimulate both antibody and cell-mediated immune responses against HIV, and is intended to protect people uninfected with HIV from contracting the disease.
- Primary indication
- Investigated for use/treatment in HIV infection and HIV prevention.Curator reviewed
- Also known as
- AAV-2 HIV Vaccine
- Code names
- TGAAC09
What you can answer from here — as of April 02, 2025
Which companies are running trials of TGAAC09, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account